These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12921002)

  • 1. [Vaccination programs: what and why should be monitoring].
    Hryniewicz W
    Przegl Epidemiol; 2003; 57 Suppl 1():63-8. PubMed ID: 12921002
    [No Abstract]   [Full Text] [Related]  

  • 2. [The necessity for factual and correct information about the most current vaccination schedule].
    Radzikowski A
    Przegl Epidemiol; 2003; 57 Suppl 1():83-7. PubMed ID: 12921004
    [No Abstract]   [Full Text] [Related]  

  • 3. [Various sides of influenza. Part II--epidemiology, influenza surveillance and prophylaxis].
    Machała MK; Brydak LB
    Pol Merkur Lekarski; 2006 Sep; 21(123):277-85. PubMed ID: 17163191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined vaccines in European Union].
    Bernatowska E; Klaudel-Dreszler M
    Przegl Epidemiol; 2004; 58 Suppl 1():44-50. PubMed ID: 15807157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of standardized case definitions and guidelines for adverse events following immunization.
    Kohl KS; Gidudu J; Bonhoeffer J; Braun MM; Buettcher M; Chen RT; Drammeh B; Duclos P; Heijbel H; Heininger U; Hummelman E; Jefferson T; Keller-Stanislawski B; Loupi E; Marcy SM
    Vaccine; 2007 Aug; 25(31):5671-4. PubMed ID: 17400339
    [No Abstract]   [Full Text] [Related]  

  • 7. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 8. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 9. [More equal vaccination schedules in the European Union needed].
    Carlsson RM; Gothefors L; Granström M
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1665-9. PubMed ID: 18590008
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
    Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
    Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postlicensure epidemiology of childhood vaccination: the Danish experience.
    Hviid A
    Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Declaration of the National Institute of Public Health - National Institute of Hygiene on safety of vaccines and vaccinations].
    Wysocki MJ; Zieliński A; Brydak LB; Bucholc B;
    Przegl Epidemiol; 2010; 64(1):105-7. PubMed ID: 20499669
    [No Abstract]   [Full Text] [Related]  

  • 13. [Economic aspects of health care in relation to vaccination programs].
    Kuszewski K
    Przegl Epidemiol; 2003; 57 Suppl 1():9-13. PubMed ID: 12920999
    [No Abstract]   [Full Text] [Related]  

  • 14. New vaccines--new dilemmas.
    Passwell JH; Spirer Z
    Isr Med Assoc J; 2005 Jun; 7(6):397-9. PubMed ID: 15984386
    [No Abstract]   [Full Text] [Related]  

  • 15. The "Green Channel" of the Veneto region as a model for vaccine safety monitoring in Italy.
    Zanoni G; Ferro A; Valsecchi M; Tridente G
    Vaccine; 2005 Mar; 23(17-18):2354-8. PubMed ID: 15755627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccines for children and adolescents].
    Knuf M; Kieninger-Baum D; Habermehl P
    MMW Fortschr Med; 2009 Apr; 151(14):28-31; quiz 32. PubMed ID: 19504838
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenges to vaccine safety.
    Marshall GS; Gellin BG
    Prim Care; 2001 Dec; 28(4):853-68, vii. PubMed ID: 11739033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EUVAC-NET survey: national measles surveillance systems in the EU, Switzerland, Norway, and Iceland.
    Glismann S; Ronne T; Schmidt JE
    Euro Surveill; 2001 Jun; 6(6):105-10. PubMed ID: 11675538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No blame--no gain.
    Templeman-Kluit A
    CMAJ; 2008 Jan; 178(2):140-1. PubMed ID: 18195280
    [No Abstract]   [Full Text] [Related]  

  • 20. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2003 Sep; 29():1-15. PubMed ID: 14524195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.